| Annual · values | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Gross Margin | 77.68% | 76.72% | — | — |
| Operating Margin | -16.49% | -19.08% | — | — |
| EBITDA Margin | -11.15% | -12.88% | — | — |
| Net Margin | -21.17% | -21.08% | — | — |
| Current Ratio | — | — | — | — |
| Quick Ratio | — | — | — | — |
| Debt / Equity | 0.41 | -0.38 | 0.08 | — |
| ROE | -19.97% | 15.17% | — | — |
| ROA | -8.46% | -7.35% | — | — |
| Asset Turnover | 0.40 | 0.35 | — | — |
| Book Value / Share | 1.08 | -1.05 | — | — |
YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.